Results 41 to 50 of about 1,265,615 (248)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Frontiers in Oncology, 2019
Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially ...
Jan-Michael Werner, Viola Schweinsberg, Michael Schroeter, Michael Schroeter, Boris von Reutern, Michael P. Malter, Max Schlaak, Max Schlaak, Gereon R. Fink, Gereon R. Fink, Cornelia Mauch, Cornelia Mauch, Norbert Galldiks, Norbert Galldiks, Norbert Galldiks   +14 more
doaj   +1 more source

Immune checkpoint blockade in infectious diseases [PDF]

, 2018
The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral ...
Wykes, MN, Lewin, SR
core   +1 more source

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

, 2022
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches.
Everest-Dass, Arun V, Kirchhammer, Nicole, Petrone, Adam, Glatz, Katharina, Barenwaldt, Anne, Sanin, David E, Mantuano, Natalia Rodrigues, Jacob, Francis, Coelho, Ricardo, Wang, Jinyu, Stanczak, Michal A, Gray, Melissa A, Monaco, Gianni, Kashyap, Abhishek S, Trefny, Marcel P, et al.   +15 more
core   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF-β as a Companion Target for Checkpoint Blockade Immunotherapy

Frontiers in Cell and Developmental Biology, 2021
Extrinsic factors such as expression of PD-L1 (programmed dealth-ligand 1) in the tumor microenvironment (TME) have been shown to correlate with responses to checkpoint blockade therapy.
Bjarne Bartlett, Bjarne Bartlett, Zitong Gao, Zitong Gao, Monique Schukking, Monique Schukking, Mark Menor, Vedbar S. Khadka, Muller Fabbri, Peiwen Fei, Youping Deng, Youping Deng   +11 more
doaj   +1 more source

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade [PDF]

, 2020
Immune checkpoint inhibitors are becoming standard treatments in several cancer types, profoundly changing the prognosis of a fraction of patients. Currently, many efforts are being made to predict responders and to understand how to overcome resistance ...
Ingangi V., Pinton L., Masetto E., Marigo I., Peranzoni E.   +4 more
core   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer

Bladder Cancer
Background: Increasing evidence supporting the role of immune checkpoint blockade in cancer management has been bolstered by recent reports demonstrating significant and durable clinical responses across multiple tumour types, including metastatic ...
S. Bidnur, R. Savdie, P.C. Black
doaj   +1 more source

Vaccination-enabled immune readiness for checkpoint blockade

Frontiers in Immunology
Immune checkpoint blockade has transformed cancer therapy by demonstrating that durable tumour control can be achieved through immune modulation rather than direct cytotoxicity.
Jhommara Bautista, Andrés López-Cortés   +1 more
doaj   +1 more source

EpCAM⁺ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response. [PDF]

Adv Sci (Weinh)
A highly sensitive SERS‐based platform measures PD‐L1 expression on EpCAM+ circulating EVs from cancer patients undergoing immunotherapy. Monitoring dynamic changes after treatment reveals that reduced EpCAM+ EV PD‐L1 levels associate with improved long‐term clinical outcomes, establishing a non‐invasive approach for tracking immune checkpoint ...
Mun B, Kim J, Kim CG, Go S, Han M, Ouck Y, Jang S, Son SU, Kim G, Son W, Kim E, Hong MH, Yeo JH, Lim EK, Kim HR, Haam S.   +15 more
europepmc   +2 more sources